A Drug Being Developed to Treat Epidermolysis Bullosa Has Been Granted Orphan Drug Status
Source: Pixabay

A Drug Being Developed to Treat Epidermolysis Bullosa Has Been Granted Orphan Drug Status

The Boston-based biopharmaceutical company Berg LLC has announced that their experimental drug candidate BPM 31510 (ubidecarenone) has been awarded Orphan Drug designation by the US Food and Drug Administration (FDA)…

Continue Reading A Drug Being Developed to Treat Epidermolysis Bullosa Has Been Granted Orphan Drug Status
Osteoarthritis Medicine May Offer Hope for Butterfly Children with EBS-DM
source: pixabay.com

Osteoarthritis Medicine May Offer Hope for Butterfly Children with EBS-DM

Epidermolysis bullosa (EB) is a rare disorder, in which a genetic mutation disrupts the production of a protein that holds the skin together. This creates intense and painful blistering externally,…

Continue Reading Osteoarthritis Medicine May Offer Hope for Butterfly Children with EBS-DM